7 completed, 4 unknown, 1 active not recruiting. 4 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 2, Unknown 2 |
| Phase 2 | 1 | Completed 1 |
Follow Canadian Medical and Surgical Knowledge Translation Research Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Vascular Regenerative Cell Exhaustion in Individuals Without Type 2 Diabetes Who Are of South Asian or European Origins Cardiovascular Diseases Risk | Active not recruiting | Canadian Medical and Surgical Knowledge Translation Research Group | 120 | 2025-01-30 | 2026-08-06 | |
| Lipoprotein (a) and Vascular Regenerative Cell Content Cardiovascular Diseases, Atherosclerosis Cardiovascular Disease | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 40 | 2024-10-05 | 2025-12-29 | |
| Vascular Regenerative Cell Exhaustion in Adults With Peripheral Artery Disease (PAD-VRCE) Peripheral Vascular Diseases, Cardiovascular Disease | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 40 | 2024-10-05 | 2026-08-21 | |
| Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion Diabetes Mellitus, Type 2 | Unknown | Canadian Medical and Surgical Knowledge Translation Research Group | 90 | 2023-11-01 | 2023-11-13 | |
| Semaglutide and Vascular Regeneration Semaglutide Pen Injector - Atherosclerosis, Cardiovascular Diseases | Phase 4 | Unknown | Canadian Medical and Surgical Knowledge Translation Research Group | 100 | 2023-04-29 | 2023-07-25 |
| Pro-vascular Regenerative Cell Exhaustion in Women With Polycystic Ovarian Syndrome Polycystic Ovary Syndrome | Unknown | Canadian Medical and Surgical Knowledge Translation Research Group | 30 | 2022-06-01 | 2022-06-08 | |
| Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA) Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 200 | 2022-03-05 | 2023-03-27 | |
| The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion Diabetes, Type 1 Diabetes | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 120 | 2022-01-08 | 2023-02-09 | |
| Empagliflozin and Cardiac Remodelling in People Without Diabetes Empagliflozin, Placebo - Cardiovascular Diseases, Left Ventricular Hypertrophy | Phase 4 | Completed | Unity Health Toronto | 169 | 2021-04-01 | 2023-02-17 |
| The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] - Cardiovascular Diseases, Cardiovascular Risk Factor | Phase 4 | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 70 | 2020-09-24 | 2024-04-02 |
| A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy Evolocumab - Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis | Phase 4 | Unknown | Canadian Medical and Surgical Knowledge Translation Research Group | 60 | 2020-08-28 | 2022-05-02 |
| An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 Icosapent ethyl - COVID-19, Inflammatory Response | Phase 2 | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 100 | 2020-06-04 | 2021-12-22 |
Cardiovascular Diseases (7) · Diabetes Mellitus, Type 2 (5) · Atherosclerosis (2) · Myocardial Ischemia (2) · Peripheral Vascular Diseases (2) · COVID-19 (1) · Carotid Stenosis (1) · Chronic Disease (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Dyslipidemias (1) · Hypertriglyceridemia (1) · Hypertrophy, Left Ventricular (1) · Inflammation (1)
eicosapentaenoic acid ethyl ester (2) · empagliflozin (1) · evolocumab (1) · semaglutide (1)
Canada (12) · Taiwan (1)
David A Hess, PhD (7) · Subodh Verma, MD, PhD (7) · Subodh Verma, MD (2) · David Mazer, MD (1) · Deepak L Bhatt, MD, MPH (1) · Hwee Teoh, PhD (1) · Mohammed Al-Omran, MD (1) · Subodh Verma, MD PhD (1)
PMID 30847424, PMID 31477497, PMID 33205058, PMID 12823351, PMID 15178579, PMID 16269619, PMID 22899443, PMID 27633186, PMID 28110911, PMID 28209728, PMID 28618138, PMID 32306097, PMID 34425083, PMID 34462732, PMID 36335517, PMID 36630964, PMID 37356446, PMID 38355246, PMID 38552629, PMID 38874618, PMID 40883226